Get the Stockscreener App
13.10
0.33%
0.06
Tonix Pharmaceuticals Holding Corp stock is traded at $13.10, with a volume of 52,619.
It is up +0.33% in the last 24 hours and down -6.15% over the past month.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
See More
Previous Close:
$13.04
Open:
$13.01
24h Volume:
52,619
Relative Volume:
0.13
Market Cap:
$186.02M
Revenue:
$13.11M
Net Income/Loss:
$-124.02M
P/E Ratio:
-0.9186
EPS:
-14.261
Net Cash Flow:
$-107.25M
1W Performance:
-5.88%
1M Performance:
-6.15%
6M Performance:
-41.96%
1Y Performance:
-26.95%
1-Day Range:
$12.90
$13.29
1-Week Range:
$12.72
$14.16
52-Week Range:
$11.60
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
13.10 | 185.24M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
440.58 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
767.27 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
786.97 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
325.48 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.20 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharmaceuticals stock hits new 52-week low: What's driving the action? - MSN
Tonix Pharmaceuticals Holding Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
Tonix Pharma CEO Lederman buys $63,099 in shares By Investing.com - Investing.com Canada
Tonix Pharma CEO Lederman buys $63,099 in shares - Investing.com
Tonix (NASDAQ: TNXP) CEO adds 5,000 shares via IRA purchase - Stock Titan
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price, news, quote and history - Yahoo Finance Australia
Tonix plans Phase 2 Lyme disease prevention study in 2027 By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Holding Corp Presents Phase 1 Data And Outlines Planned Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease - marketscreener.com
Tonix Pharma Advances TNX-4800 Lyme Disease Prevention Program - TipRanks
Tonix Pharmaceuticals (TNXP) Advances TNX-4800 Lyme Disease Trea - GuruFocus
Tonix plans Phase 2 Lyme disease prevention study in 2027 - Investing.com
Tonix Pharmaceuticals presents Phase 1 TNX-4800 data, aims for adaptive Phase 2 in H1 2027 - TradingView
Tonix (Nasdaq: TNXP) advances TNX-4800 Lyme prevention antibody on Phase 1 data - Stock Titan
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 - Yahoo Finance
Recap Report: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear marketAnalyst Upgrade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action? - Benzinga
Tonix Pharmaceuticals (NASDAQ: TNXP) puts reverse split and 2026 equity plan to vote - Stock Titan
TNXP Should I Buy - Intellectia AI
TNXP SEC FilingsTonix Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Vanguard disaggregates holdings after realignment; reports 0 shares in Tonix (TNXP) - Stock Titan
Tonix Pharmaceuticals Holding Corp. Trade Ideas — BOATS:TNXP - TradingView
Tonix doses first patient in migraine treatment study By Investing.com - za.investing.com
Tonix Pharmaceuticals Begins Phase 1 Study of Intranasal Oxytocin (TNX-1900) for Migraine and Craniofacial Pain Treatment - Minichart
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain - Bitget
Tonix Pharmaceuticals (TNXP) Advances with Phase 1 Study on TNX-1900 - gurufocus.com
Tonix Pharma Begins Phase 1 Study of TNX-1900 - TipRanks
Tonix doses first patient in migraine treatment study - Investing.com
Tonix (NASDAQ: TNXP) doses first subject in TNX-1900 migraine study - Stock Titan
Tonix Pharmaceuticals Holding Corp Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 - marketscreener.com
Q1 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
FY2028 Earnings Estimate for TNXP Issued By Zacks Research - Defense World
Why (TNXP) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
FY2028 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
Tonix Pharmaceuticals Holding Corp. (TNXP) Presents at BIO-Europe Spring 2026Slideshow - Seeking Alpha
TNXP: ~2500 Patients Have Initiated Treatment with Tonmya Following November 2025 Commercial Launch - research-tree.com
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 - The Manila Times
Tonix Pharmaceuticals Announces Upcoming Presentations on TNX-4800 and TNX-801 at World Vaccine Congress 2026 - Quiver Quantitative
Lyme disease and mpox studies put Tonix on vaccine congress agenda - Stock Titan
Levels Update: What are Tonix Pharmaceuticals Holding Corps earnings expectationsEarnings Performance Report & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Tonix Pharmaceuticals (NASDAQ: TNXP) Seeks 1:2–1:250 Reverse Split; PwC Ratification - Stock Titan
Tonix Pharmaceuticals Holding Corp. Trade Ideas — LSX:A40VM0 - TradingView
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Tonix Pharmaceuticals says prescriptions for chronic pain drug top 4,200 since launch - MSN
Tonix Pharma CEO Makes Bold Insider Move Signaling Growing Confidence - TipRanks
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):